biostudies-literatureMachado ARTSão Paulo Research FoundationCoordination for the Improvement of Higher Education PersonnelCNPqNational Council for Scientific and Technological Development2582https://www.ebi.ac.uk/biostudies/studies/S-EPMC9788602biostudies-literatureUnknown14(12)Hepatocellular carcinoma is the seventh most common type of cancer in the world, with limited treatment options. A promising strategy to treat cancer is to associate chemotherapeutics and plant bioactive compounds. Here, we examined whether diallyl disulfide (DADS; 50-200 μM) and sorafenib (SORA; 8 μM), either alone or in combination, were toxic to hepatocellular carcinoma cells (HepG2) in vitro. We assessed whether DADS and/or SORA induced cell death (LIVE/DEAD assay and autophagy) and cell cycle changes (flow cytometry), altered expression of key genes and proteins (RT-qPCR and Western blot), and modulated tumorigenesis signatures, such as proliferation (clonogenic assay), migration (wound healing), and invasion (inserts). The DADS + SORA combination elicited autophagic cell death by upregulating LC3 and NRF2 expression and downregulating <i>FOS</i> and <i>TNF</i> expression; induced the accumulation of cells in the G1 phase which thereby upregulated the <i>CHEK2</i> expression; and inhibited invasion by downregulating the <i>MMP2</i> expression. Predictive analysis indicated the participation of the MAPK pathway in the reported results. The DADS + SORA combination suppressed both cell invasion and clonogenic survival, which indicated that it dampened tumor growth, proliferation, invasion, and metastatic potential. Therefore, the DADS + SORA combination is a promising therapy to develop new clinical protocols.PharmaceuticsDiallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma.PMC9788602001#2017/24576-0#302479/2019-8#168759/2018-7#2019/08348-2Antunes LMGTuttis KAissa AFMachado ARTSantos PWDSfalseDiallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma.Hepatocellular carcinoma is the seventh most common type of cancer in the world, with limited treatment options. A promising strategy to treat cancer is to associate chemotherapeutics and plant bioactive compounds. Here, we examined whether diallyl disulfide (DADS; 50-200 μM) and sorafenib (SORA; 8 μM), either alone or in combination, were toxic to hepatocellular carcinoma cells (HepG2) in vitro. We assessed whether DADS and/or SORA induced cell death (LIVE/DEAD assay and autophagy) and cell cycle changes (flow cytometry), altered expression of key genes and proteins (RT-qPCR and Western blot), and modulated tumorigenesis signatures, such as proliferation (clonogenic assay), migration (wound healing), and invasion (inserts). The DADS + SORA combination elicited autophagic cell death by upregulating LC3 and NRF2 expression and downregulating <i>FOS</i> and <i>TNF</i> expression; induced the accumulation of cells in the G1 phase which thereby upregulated the <i>CHEK2</i> expression; and inhibited invasion by downregulating the <i>MMP2</i> expression. Predictive analysis indicated the participation of the MAPK pathway in the reported results. The DADS + SORA combination suppressed both cell invasion and clonogenic survival, which indicated that it dampened tumor growth, proliferation, invasion, and metastatic potential. Therefore, the DADS + SORA combination is a promising therapy to develop new clinical protocols.2022-01-01T00:00:00Z2022 Nov2025-04-04T07:59:30.211Z2025-04-04T07:59:30.211ZS-EPMC97886023655907610.3390/pharmaceutics14122582